Relative bioavailability.
Conditions
Interventions
Intervention 1: Intervention group 1: Two tablets of Raha pharmaceutical company alprazolam 0.5 mg simultaneously. Intervention 2: Intervention group 2: Two tablets of Pfizer pharmaceutical company
Sponsors
Raha Pharmaceutical Company
Eligibility
Sex/Gender
Male
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Gender: Male Age between 18 and 50 years The volenteer is willing to do the study and can sign and submit the informed consent form The candidate is fully present during the study and according to the consent form, believes in and adheres to the implementation of the study protocol Candidate must have a specific place of residence and a landline Normal clinical and laboratory results
Exclusion criteria
Exclusion criteria: History of allergy or allergy to alprazolam Any history of hypersensitivity or intolerance that, in the opinion of the researcher, reduces the safety of the study volunteers Any history of chronic infectious disease, systemic defects, or organ dysfunction Presence of gastrointestinal disease or a history of malabsorption in the last year A history of a medical problem over the last year that required medication or hospitalization Drugs that significantly induce or inhibit drug-metabolizing enzymes that be used within 30 days prior to administration Receive any medication from previous research studies within 30 days prior to the current study Donation or loss of significant amounts of blood (480 ml or more) within 30 days prior to current study Smokers or addicts
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of Cmax, Tmax and AUC and comparison of blood profiles of the two drugs. Timepoint: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 24, 36h. Method of measurement: HPLC analysis. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAkram Sharifian
Esfahan University of Medical Sciences
Outcome results
None listed